Skip to content
Parakho

Kwality Pharmaceuticals Ltd

NSE KPLBSE 539997kwalitypharma.com

Statement of profit and loss

Parakho has not ingested a filed result for this company on a consolidated basis. When the company files one with the exchange, it appears here automatically.

Earnings call

Q4 FY26

Kwality Pharmaceuticals reported Q4 FY26 revenue of Rs157.1 crore, up 35.8% year-on-year, and full-year FY26 revenue of Rs503 crore, up nearly 36% from Rs370 crore in FY25. EBITDA margins expanded from 22% to 24% and profit after tax grew 69% to Rs67 crore, with management citing improved cash conversion cycle and recovery of delayed Middle East receivables. Management reiterated FY27 targets of Rs650-700 crore revenue and Rs100 crore PAT, alongside a longer-term aspiration of Rs1,000 crore revenue by FY29.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 34 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 13 Aug 2026.